|Kommanditgesellschaft auf Aktien with Societas Europaea as partner with unlimited liability|
|Traded as||FWB: FRE|
Euro Stoxx 50 component
|Stephan Sturm (CEO and chairman of the management board)|
Gerd Krick (Chairman of the supervisory board)
|Products||infusion pumps, medication, hospitals, medical care|
|Revenue||€29.083 billion (2016)|
|€4.327 billion (2016)|
|€1.593 billion (2016)|
|Total assets||€46.447 billion (2016)|
|Total equity||€20.420 billion (2016)|
|Owner||Else Kröner-Fresenius-Foundation, BlackRock, Henderson Group, Capital Group Companies, Allianz Global Investors|
Number of employees
|277,318 (2019) |
|Footnotes / references|
Fresenius SE & Co. KGaA is a health care company based in Bad Homburg vor der Höhe, Germany. The company provides products and services for dialysis, hospitals as well as inpatient and outpatient medical care. The company also focuses on hospital management as well as on engineering and services for medical centers and other health care facilities.
The company is made up of four divisions:
- Fresenius Medical Care, a publicly traded company of which Fresenius owns 30.8%, focuses on patients with chronic kidney failure. With a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States.
- Fresenius Helios is the largest hospital operator and provider of inpatient and outpatient in Germany. The Helios Kliniken has more than 110 hospitals and more than 30,000 beds, treating over 4 million patients annually.
- Fresenius Kabi is a supplier of essential drugs, clinical nutrition products, and medical devices. It produces generic versions of intravenous oncology products such as Paclitaxel, Irinotecan, Oxaliplatin, Gemcitabine, Cytarabine, Carboplatin, Topotecan, Docetaxel, and Epirubicin.
- Fresenius Vamed develops and manages health care facilities.
- Fresenius SE & Co. KGaA
- Fresenius Medical Care
- NxStage Medical, Inc.
- Fresenius Helios
- Helios Kliniken GmbH
- Humaine Kliniken
- IDC Salud Holding S.L.U. (Quirónsalud)
- Damp Group
- Helios Kliniken GmbH
- Fresenius Kabi AG
- Labesfal SA
- Fresenius Kabi Oncology Plc
- Dabur Pharma Ltd
- APP Pharmaceuticals, Inc
- Fenwal Holdings, Inc.
- Fresenius Vamed
- Fresenius Medical Care
In 1946, Fresenius died. Else Kröner, his foster-daughter and protegée, who was still in pharmacy school at the time, inherited the company. Else Kröner rescued the company from significant debts by laying off the majority of staff and restructuring the business. Kröner died in 1988. Kröner's will left all of her assets to the Else Kröner-Fresenius-Foundation, which funds medical research.
In 2001, the company acquired Wittgensteiner Kliniken, a major operator of private hospitals in Germany.
In 2005, the company acquired Helios.
In September 2006, Helios Kliniken acquired a majority stake in Humaine Kliniken. HUMAINE operates six acute and post acute care hospitals in the fields of neurology, oncology and traumatology.
On July 16, 2007, the company completed its conversion from an Aktiengesellschaft (AG - German public limited company) to a Societas Europaea, the European Union-wide equivalent. The company changed its legal status once again on January 28, 2011, becoming a Kommanditgesellschaft auf Aktien (KGaA - German partnership limited by shares) with a Societas Europaea as a partner with unlimited liability (SE & Co. KGaA).
In August 2008, Fresenius Kabi acquired 73.3% of Dabur Pharma of India.
In September 2008, Fresenius Kabi acquired APP Pharmaceuticals, Inc.
In October 2011, the company agreed to acquire 51% of the share capital in Katholisches Klinikum Duisburg hospital.
Also in October 2011, Helios Kliniken acquired 94.7% of the share capital in Damp Group.
In November 2014, the company announced that its Russian partners, Sistema and Zenitco Finance Management, agreed to terminate their joint venture agreement that had been established in April 2014. The termination was prompted by changing political and regulatory circumstances in the region.
In January 2017, Fresenius acquired the largest Spanish hospital group, the Grupo Hospitalario Quirónsalud for €5.76 billion and merged it into the Helios Group, establishing the biggest hospital group of Europe.
Concerns of use of hydroxyethyl starch and threats against researcher
In 2012, a paper was published raising concerns regarding the use of hydroxyethyl starch in sepsis. Fresenius Kabi, which makes the product, threatened legal action against the main author, Danish scientist Anders Perner.
Supply of faulty insulin syringes
In 2015, Fresenius Kabi Group pleaded guilty to breaches of United Kingdom's Medicines Act 1968 and was fined £500,000 by the Sheffield Crown Court for supplying faulty insulin syringes containing no insulin, leading to the death of Neil Judge from diabetic ketoacidosis in 2010.
- "Fresenius company profile". Retrieved September 25, 2019.
- "Annual Report". Fresenius.
- "Fresenius". Forbes.
- "Group Overview". Fresenius.
- "History - Fresenius".
- "Else Kröner-Fresenius-Stiftung (Foundation)". Fresenius.
- "Fresenius Kabi closed acquisition of I.V. drug company Labesfal" (Press release). Fresenius. March 16, 2005.
- "Fresenius Kabi continues growth strategy and acquires I.V. drug company" (Press release). Fresenius. January 7, 2005.
- "HELIOS obtains antitrust approval to acquire HUMAINE Kliniken" (Press release). Fresenius. September 11, 2006.
- "Fresenius completes conversion into a European Company (SE)" (Press release). Fresenius. July 16, 2007.
- "Fresenius implements share conversion and change of legal form – First trading day of Fresenius SE & Co. KGaA shares scheduled for January 31, 2011" (Press release). Fresenius. 28 January 2011.
- "German co Fresenius Kabi picks up 73% in Dabur Pharma". The Times of India. April 20, 2008.
- "Fresenius closes APP acquisition" (Press release). Fresenius. September 10, 2008.
- "HELIOS acquires majority of maximum care hospital in Duisburg, North-Rhine Westphalia" (Press release). Fresenius. October 31, 2011.
- "HELIOS continues expansion in German hospital market, acquires Damp Group" (Press release). Fresenius. October 12, 2011.
- Gould, Jonathan; Burger, Ludwig (September 13, 2013). "Rhoen-Klinikum to sell hospitals to Fresenius in $4 billion deal". Reuters.
- Ross, Alice (September 13, 2013). "Fresenius buys Rhön-Klinikum hospitals for €3bn". Financial Times.
- Dauer, Ulrike (June 30, 2014). "Fresenius Sells Rhoen-Klinikum Stake". The Wall Street Journal.
- "Fresenius says Fresenius Kabi and Russian partners terminate JV". Reuters. 6 November 2014.
- "Fresenius Kabi USA Acquires U.S. Pharmaceutical Plant and Ready-to-Administer Drugs from BD" (Press release). Business Wire. January 8, 2016.
- "Fresenius Helios acquires hospital in North Rhine-Westphalia with more than 500 beds" (Press release). Fresenius. February 22, 2016.
- "Fresenius Helios closes acquisition of Quirónsalud" (Press release). Fresenius. January 31, 2017.
- "Fresenius Kabi completes acquisition of Merck KGaA's biosimilars business" (Press release). Fresenius. September 1, 2017.
- "Fresenius Medical Care completes acquisition of NxStage Medical" (Press release). PR Newswire. February 26, 2019.
- BANNOW, TARA (February 26, 2019). "Fresenius Medical Care closes $2 billion NxStage acquisition". Modern Healthcare.
- Perner, Anders; Haase, Nicolai; Guttormsen, Anne B.; Tenhunen, Jyrki; Klemenzson, Gudmundur; Åneman, Anders; Madsen, Kristian R.; Møller, Morten H.; Elkjær, Jeanie M.; Poulsen, Lone M.; Bendtsen, Asger; Winding, Robert (July 12, 2012). "Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis". The New England Journal of Medicine. 367 (2): 124–34. doi:10.1056/NEJMoa1204242. PMID 22738085.
- Wojcik, Jeppe (July 24, 2012). "Pharma giant threatens Danish scientist". ScienceNordic.
- "Insulin-free syringe firms fined over diabetic death". BBC News. 9 July 2015.
- Ford, Steve (9 July 2015). "Firms fined for supplying hospital with faulty syringes". Nursing Times.
- Lynch, Sarah N.; Raymond, Nate (March 29, 2019). "Fresenius Medical Care to pay $231 million to resolve criminal, civil foreign bribery charges". Reuters.
- Kamp, Michael / Neumann, Florian: Fresenius – 100 Years. Munich: August Dreesbach Verlag, 2012. ISBN 978-3-940061-84-3.